Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
Price was the key driver for the period
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Ind-Ra expects revenue growth of over 12% in 2022.
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Subscribe To Our Newsletter & Stay Updated
